Improved bioavailability and clinical response in patients with chronic liver disease following the administration of a spironolactone: β-cyclodextrin complex

British Journal of Clinical Pharmacology

Volumn 44, Issue 1, 1997, Pages 35-39

  Abosehmah Albidy, A Z M ^a   York, P ^a   Wong, V ^b   Losowsky, M S ^b   Chrystyn, H ^a  

^a UNIVERSITY OF BRADFORD   (United Kingdom)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Bioavailability; Liver disease; Spironolactone; cyclodextrin

Indexed keywords

BETA CYCLODEXTRIN; CANRENONE; DRUG METABOLITE; SPIRONOLACTONE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BIOAVAILABILITY; BIOEQUIVALENCE; CHRONIC LIVER DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPLEX FORMATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISSOLUTION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG FORMULATION; FEMALE; FLUID BALANCE; HEALTH STATUS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STEADY STATE;

EID: 0030796999     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1997.00626.x     Document Type: Article

References (19)

1. Sadee W, Dagcioglu M, Schroder R. Pharmacokinetics of Aldactone in humans. In Extra-renal activity of Aldactone and its antagonists eds. Brendel W, Coraboeuf E, Ebling FJG. Amsterdam: Excerpta Med. 1972: 40-42.
2. Clarke JM, Ramsey LE, Shelton JR, Tidd MJ, Murray S, Palmer RF. Factors influencing comparative bioavailability of spironolactone tablets. J Pharm Sci 1977; 66: 1429-1432.
3. McInnes GI, Asbury MJ Ramsay, LE Shelton JR, Harrison IR. Effect of micronization on the bioavailability and pharmacological activity of spironolactone. J Clin Pharmacol 1982; 22: 410-417.
4. Gantt CL, Gochman N, Dyniewscz JM. Effect of a detergent on gastrointesinal absorption of a steroid. Lancet 1961; i: 486-487.
5. Gantt CL, Gochman N, Dyniewscz JM. Gastrointesinal absorption of spironolactone. Lancet 1962; i: 1130-1131.
6. Kurozumi M., Nambu N, Nagai T. Inclusion compounds of non-steroidal anti-inflammatory and other slightly suitable drugs with and α and β cyclodextrins. Chem Pharm Bull 1975; 23: 3062-3068.
7. Saenger W. Cyclodextrin inclusion compounds in research and industry. Angew Chem Int 1980; 19: 344-362.
8. Mulgaard Anderson F, Bundguard H. Inclusion complexation of spironolactone with cyclodextrins. Arch Pharm Chem Sci Ed. 1983; 11: 7-14.
9. Debruères B, Brètillon A, Duchène D. Improvement of solubility and bioavailability of spironolactone by inclusion in β-cyclodextrin. Proc Int Symp Control Rel Bioact Mater 1985; 12: 118-119.
10. Seo H, Sunuoka M, Hashimoto T, Otagiri M, Uekama K. Enhancement of oral bioavailability of spironolactone by inclusion in cyclodextrin. Chem Pharm Bull 1983; 31: 286-291.
11. Uekema K. Pharmaceutical applications of methylated cyclodextrins. Pharm Int 1985; 6: 61-65.
12. Vila-Jato JL, Blanco J, Vilar A. Spironolactone/-cyclodextrin complex: oral bioavailability in humans. Acta Pharm Technol 1986; 32: 82-85.
13. Yusuff NT, York P, Chrystyn H, et al. Improved bioavailability from a spironolactone beta-cyclodextrin complex. Eur J Clin Pharmacol 1991; 410: 507-511.
14. Levy G. Availability of spironolactone given by mouth. Lancet 1962; ii: 723-724.
15. Krause W, Karrus J, Seifert W. Pharmacokinetics of canrenone after oral administration of spironolactone and intravenous injection of canrenoate K in healthy man. Eur J Clin Pharmacol 1983; 25: 449-613.
16. Abshagen U, Besenfelder E, Endele R, Koch K, Neubert B. Kinetics of canrenone after single and multiple doses of spironolactone. Eur J Clin Pharmacol 1979; 16: 255-262.
17. Overdiek JWPM, Merkus FWHM. Influence of food on the bioavailability of spironolactone. Clin Pharm 1986; 40: 531-536.
18. Gardiner P, Martin BIC, Boreham DR, et al. Spironolactone metabolism: Steady State serum levels of the sulphur containing metabolites. J Clin Pharmacol 1989; 29: 342-347.
19. Melander A, Danielson K, Scherston B, Thulin T, Wåhlin E. Enhancement by food of canrenone bioavailability from spironolactone. Clin Pharmacol Ther 1977; 22: 100-103.